

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-97. (Canceled).

98. (Currently Amended) A combination comprising a liposome and a compound according to claim ~~[[61]]~~120.

99. (Currently Amended) A method for the production of a lipid compound according to claim ~~[[61]]~~120.

100. (Currently Amended) A cosmetic formulation comprising a lipid compound according to claim ~~[[61]]~~120.

101. (Currently Amended) A pharmaceutical composition comprising a compound according to claim ~~[[61]]~~120.

102. (Currently Amended) A method of treating a condition chosen from syndrome X, obesity or an overweight condition, hypertension, fatty liver, diabetes, hyperglycaemia, hyperinsulinemia, insulin resistance, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia (HTG), and stenosis, comprising administering to a subject in need thereof an effective amount of a compound according to claim ~~[[61]]~~120 or a pharmaceutically acceptable salt thereof.

103. (Currently Amended) The method according to claim 102, for producing weight loss or a reduction of fat mass in a human or non-human animal in need thereof, ~~comprising administering thereto an effective amount of a compound according to claim 61 or a pharmaceutically acceptable salt thereof.~~

104. (Currently Amended) A method for the treatment of inflammatory disorders, comprising administering to a subject in need thereof an effective amount of a compound according to claim [[61]]120 or a pharmaceutically acceptable salt thereof.

105. (Currently Amended) A method of lowering concentration of cholesterol and triglycerides in the blood of mammals and/or inhibiting the oxidative modification of low density lipoprotein, comprising administering to a subject in need thereof an effective amount of a compound according to claim [[61]]120 or a pharmaceutically acceptable salt thereof.

106. (Currently Amended) A method for producing weight loss or a reduction of the fat mass in a human or non-human animal in need thereof, comprising administering thereto an effective amount of a compound according to claim [[61]]120 or a pharmaceutically acceptable salt thereof.

107. (Currently Amended) A method for the modification of the fat distribution and content of animals, comprising administering to a subject in need thereof an effective amount of a compound according to claim [[61]]120 or a pharmaceutically acceptable salt thereof.

108. (Currently Amended) A method of inhibiting the growth of tumours, comprising administering to a subject in need thereof an effective amount of a compound according to claim [[61]]120 or a pharmaceutically acceptable salt thereof.

109. (Currently Amended) A method for the treatment or inhibition of primary and secondary metastatic neoplasms, comprising administering to a subject in need thereof an effective amount of a compound according to claim [[61]]120 or a pharmaceutically acceptable salt thereof.

110. (Currently Amended) A method for the treatment of proliferative skin disorders, comprising administering to a subject in need thereof an effective amount of a compound according to claim ~~[[61]]~~120 or a pharmaceutically acceptable salt thereof.

111. (Currently Amended) A method for the inhibition of proliferation or induction of differentiation of keratinocytes, comprising administering to a subject in need thereof an effective amount of a compound according to claim ~~[[61]]~~120 or a pharmaceutically acceptable salt thereof.

112. (Currently Amended) A method for the treatment of inflammatory disorders, comprising administering to a subject in need thereof an effective amount of a compound according to claim ~~[[61]]~~120 or a pharmaceutically acceptable salt thereof.

113. (Currently Amended) A method for enhancing the endogenous production of interleukin-10 (IL-10) in mammalian cells or tissues, comprising administering to a subject in need thereof an effective amount of a compound according to claim ~~[[61]]~~120 or a pharmaceutically acceptable salt thereof.

114. (Currently Amended) A method for suppression of the endogenous production of interleukin-2 (IL-2) in mammalian cells or tissues, comprising administering to a subject in need thereof an effective amount of a compound according to claim ~~[[61]]~~120 or a pharmaceutically acceptable salt thereof.

115. (Currently Amended) A method for the inhibition of proliferation of stimulated peripheral mononuclear cells (PBMC), comprising administering to a subject in need thereof an effective amount of a compound according to claim ~~[[61]]~~120 or a pharmaceutically acceptable salt thereof.


116. (Previously Presented) The pharmaceutical composition according to claim 101, admixed with at least one of a pharmaceutically acceptable carrier, diluent, excipient, or adjuvant.


117. (Previously Presented) A topically administrable pharmaceutical composition according to claim 116.



118. (Previously Presented) A parenterally administrable pharmaceutical composition according to claim 116.

119. (Previously Presented) An intravenously administrable pharmaceutical composition according to claim 116.

120. (New) A compound chosen from







, or

